» Articles » PMID: 35669406

Rules of Engagement: Promoting Academic-industry Partnership in the Era of Digital Pathology and Artificial Intelligence

Abstract

Academic industry partnership (AIP) represents an important alliance between academic researchers and industry that helps translate technology and complete the innovation cycle within academic health systems. Despite diverging missions and skillsets the culture for academia and industry is changing in response to the current digital era which is spawning greater collaboration between physicians and businesses in this marketplace. In the field of pathology, this is further driven by the fact that traditional funding sources cannot keep pace with the innovation needed in digital pathology and artificial intelligence. This concept article from the Digital Pathology Association (DPA) describes the rules of engagement for pathology innovators in academia and for their corporate partners to help establish best practices in this critical area. Stakeholders include pathologists, basic and translational researchers, university technology transfer and sponsored research offices, as well as industry relations officers. The article discusses the benefits and pitfalls of an AIP, reviews different partnership models, examines the role of pathologists in the innovation cycle, explains various agreements that may need to be signed, covers conflict of interest and intellectual property issues, and offers recommendations for ensuring successful partnerships.

Citing Articles

Artificial intelligence and digital pathology: clinical promise and deployment considerations.

Zarella M, McClintock D, Batra H, Gullapalli R, Valante M, Tan V J Med Imaging (Bellingham). 2023; 10(5):051802.

PMID: 37528811 PMC: 10389766. DOI: 10.1117/1.JMI.10.5.051802.


The slow-paced digital evolution of pathology: lights and shadows from a multifaceted board.

Caputo A, LImperio V, Merolla F, Girolami I, Leoni E, Della Mea V Pathologica. 2023; 115(3):127-136.

PMID: 37387439 PMC: 10462988. DOI: 10.32074/1591-951X-868.

References
1.
Rasmussen K, Bero L, Redberg R, Gotzsche P, Lundh A . Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ. 2018; 363:k3654. PMC: 6169401. DOI: 10.1136/bmj.k3654. View

2.
Sunderland J . The Academic NDA: Justification, Process, and Lessons Learned. J Nucl Med. 2020; 61(4):480-487. DOI: 10.2967/jnumed.119.238287. View

3.
Tsai W, Erickson S . Early-stage biotech companies: strategies for survival and growth. Biotechnol Healthc. 2013; 3(3):49-53. PMC: 3571061. View

4.
Pantanowitz L, Sharma A, Carter A, Kurc T, Sussman A, Saltz J . Twenty Years of Digital Pathology: An Overview of the Road Travelled, What is on the Horizon, and the Emergence of Vendor-Neutral Archives. J Pathol Inform. 2019; 9:40. PMC: 6289005. DOI: 10.4103/jpi.jpi_69_18. View

5.
Mas J, Hsueh B . An investor perspective on forming and funding your medical device start-up. Tech Vasc Interv Radiol. 2017; 20(2):101-108. DOI: 10.1053/j.tvir.2017.04.003. View